Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas

Bone Marrow Transplantation

Volumn 30, Issue 4, 2002, Pages 207-214

  Castagna, L ^a   Bertuzzi, A ^a   Nozza, A ^a   Siracusano, L ^a   Balzarotti, M ^a   Magagnoli, M ^a   Sarina, B ^a   Timofeeva, I ^a   Sinnone, M ^b   Grimoldi, M G ^c   Fare M ^d   Santoro, A ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b SAN PAOLO HOSPITAL   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d Centro Trasfusionale e di Immunoematologia   (Italy)

Author keywords

Allogeneic transplantation; Immunotherapy; Low intensity conditioning regimen

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DRUG DERIVATIVE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VIDARABINE; ACICLOVIR; BLEOMYCIN; COTRIMOXAZOLE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; INTERLEUKIN 2; MELPHALAN; PREDNISONE; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN E1; STEROID; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; ALLOTRANSPLANTATION; ARTICLE; CLINICAL TRIAL; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; NEOPLASM; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PILOT STUDY; STEM CELL MOBILIZATION; SURVIVAL; CANCER REGRESSION; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEASIBILITY STUDY; GLYCOSYLATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; INFECTION; LEUKOCYTE COUNT; MUCOSA INFLAMMATION; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SAFETY; SOLID TUMOR; THROMBOCYTE COUNT; TREATMENT OUTCOME; VEIN OCCLUSION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASMS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PILOT PROJECTS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 0036672762     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703626     Document Type: Article

References (34)

1. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
2. Engraftment kinetics after non myeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses
3. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer
4. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
5. Kinetics of recovery of CD4+ T cells in peripheral blood of deoxycoformycin-treated patients
6. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: Safety, kinetics of mobilization, and composition of the graft
7. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells
8. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease
9. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: A mechanism for monocyte-mediated suppression of T-cell proliferation
10. Randomized trial of bone marrow versus lenogastrim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Societe Française de greffe de moelle
11. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: A randomised trial
12. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukemia: First results of a randomised multicentre trial of the European Group for Marrow Transplantation
13. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers
14. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow
15. Tolerance induction by 'megadose' hematopoietic transplants: Donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture
16. Mixed hematopoietic chimerism following bone marrow transplantation for hematologic malignancies
17. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease
18. T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation
19. Mixed chimerism: Preclinical studies and clinical applications
20. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors
21. IBMTR severity index for grading acute graft-versus-host disease: Retrospective comparision with Glucksberg grade
22. Guidelines for the use of antimicrobial infectious agents in neutropenic patients with unexplained fever
23. Nonmyeloablative hemopoietic cell transplantation
24. Non-myeloablative stem cell transplants
25. Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy
26. Dose-reduced conditioning for allogeneic blood stem cell transplantation: Durable engraftment without antithymocyte globulin
27. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma
28. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease
29. Immunotherapy by non-myeloablative allogeneic stem cell transplantation in multiple myeloma: Results of a pilot study as salvage therapy after autologous transplantation
30. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
31. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
32. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hemopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma
33. Reduced-intensity conditioning reduces the risk of sever infections after allogeneic peripheral blood stem cell transplantation
34. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation